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VV ECMO for Treatment of Severe ARDS in CoVID-19 Patients at UNMC
Abstract
Abstract
Introduction: Veno-venous extracorporeal membrane oxygenation (VV ECMO) is an indicated treatment
for severe acute respiratory distress syndrome (ARDS) refractory to conventional medical treatment.
Severe ARDS is a common complication of CoVID-19 infection. Subsequently, the efficacy of VV ECMO in
CoVID-19 severe ARDS patients must be investigated. ECMO is a resource-intensive treatment modality,
meaning that its use must be reserved for patients with robust indications and paucity of
contraindications.
Methods: We performed retrospective chart review of three patients at the University of Nebraska Medical
Center that were placed on VV ECMO secondary to severe ARDS from CoVID-19 infection.
Results: All patients were male with a median age of 39 years. Two patients were of Hispanic descent,
and the third was of Asian descent. No patients had underlying lung disease, and all patients had type II
diabetes mellitus. Median time on mechanical ventilation prior to ECMO cannulation was six days.
Median duration of ECMO treatment was 21 days with a range of 17 to 27 days. All patients were
decannulated from ECMO during their hospital stay, and all patients survived to 60 days post-hospital
discharge. Complications while on ECMO included GI bleeding in two patients, hematuria in one patient,
necessitation of vasodilator and vasopressor support in all patients, AKI in two patients, secondary
bacterial pneumonia in two patients, and blood cultures positive for gram-positive organisms in all
patients. No patients suffered DVT or CVA. All patients required pRBC transfusion during ECMO
treatment. Two patients were treated with remdesivir and one patient received baricitinib, a JAK-inhibitor.
Conclusion: VV ECMO is a viable treatment for patients with severe ARDS secondary to CoVID-19
infection that have failed conventional therapy. Stringent adherence to inclusion and exclusion criteria is
imperative. VV ECMO combined with lung protective ventilation strategies with a focus on minimizing
driving pressure can provide life-saving treatment to patients with severe ARDS secondary to CoVID-19
infection
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Abstract
9HQRYHQRXVH[WUDFRUSRUHDOPHPEUDQH
R[\JHQDWLRQ 99(&02 LVDQLQGLFDWHG
treatment for severe acute respiratory distress
syndrome (ARDS) refractory to conventional
medical treatment. Severe ARDS is a common
FRPSOLFDWLRQRI&29,'LQIHFWLRQ
6XEVHTXHQWO\WKHHI¿FDF\RI99(&02LQ
&29,'UHODWHGVHYHUH$5'6SDWLHQWV
must be investigated. ECMO is a resourceintensive treatment modality, meaning that its
use must be reserved for patients with robust
indications and paucity of contraindications.
We performed a retrospective chart review of
three patients at the University of Nebraska
0HGLFDO&HQWHUWKDWZHUHSODFHGRQ99
ECMO secondary to severe ARDS from
&29,'LQIHFWLRQ$OOSDWLHQWVZHUHPDOH
with a median age of 39 years. Two patients
were of Hispanic descent, and the third was
of Asian descent. No patients had underlying
OXQJGLVHDVHDQGDOOSDWLHQWVKDGW\SH,,
diabetes mellitus. Median time on mechanical
ventilation prior to ECMO cannulation was
six days. Median duration of ECMO treatment
was 21 days with a range of 17 to 27 days.
All patients were decannulated from ECMO
during their hospital stay, and all patients
survived to 60 days post-hospital discharge.
Complications while on ECMO included
*,EOHHGLQJLQWZRSDWLHQWVKHPDWXULDLQ
one patient, necessitation of vasodilator and
YDVRSUHVVRUVXSSRUWLQDOOSDWLHQWV$.,LQ
two patients, secondary bacterial pneumonia
in two patients, and blood cultures positive
for gram-positive organisms in all patients.
1RSDWLHQWVVXIIHUHG'97RU&9$$OO
patients required pRBC transfusion during
ECMO treatment. Two patients were treated
with remdesivir and one patient received
EDULFLWLQLED-$.LQKLELWRU99(&02LV
a viable treatment for patients with severe
$5'6VHFRQGDU\WR&29,'LQIHFWLRQWKDW
have failed conventional therapy. Stringent
adherence to inclusion and exclusion criteria
LVLPSHUDWLYH99(&02FRPELQHGZLWKOXQJ
protective ventilation strategies with a focus
on minimizing driving pressure can provide
life-saving treatment to patients with severe
$5'6VHFRQGDU\WR&29,'LQIHFWLRQ

with more than 540,000 deaths.1 Between
March 1, 2020, and August 16, 2020, the
U.S. experienced 260,000 more deaths than
WKH¿YH\HDUDYHUDJHIRUWKDWSHULRG2 Peak
daily hospital admissions of patients with
FRQ¿UPHG&29,'LQWKH86ZHUH
over 18,000 in early January 2021.3 Twenty
percent of hospitalized patients in New York
&LW\UHTXLUHG,&8OHYHOFDUHZLWKURXJKO\
RI,&8SDWLHQWVUHTXLULQJPHFKDQLFDO
ventilation.4
Extracorporeal membrane oxygenation
(ECMO) is a viable treatment for severe acute
respiratory distress syndrome (ARDS) due to
YDULRXVFDXVHV9HQRYHQRXVH[WUDFRUSRUHDO
PHPEUDQHR[\JHQDWLRQ 99(&02 LVWKH
most common modality of extracorporeal
support used for severe respiratory failure
not amenable to medical interventions.599
ECMO is a device that replaces native lung
function in situations of severe pulmonary
IDLOXUHW\SLFDOO\GXHWR$5'6,WIXQFWLRQV
by utilizing a membrane lung to provide
oxygen and remove carbon dioxide, then
returning oxygenated blood back to the
SDWLHQW,QSDWLHQWVZLWKERWKUHVSLUDWRU\DQG
FDUGLDFIDLOXUHYHQRDUWHULDO 9$ (&02
can provide surrogate pulmonary and cardiac
function. At many medical institutions,
LQFOXGLQJRXURZQ99(&02KDVEHHQXVHG

to treat patients with severe ARDS, bacterial
or viral pneumonia, status asthmaticus,
EURQFKRSOHXUDO¿VWXODVDQGPHGLDVWLQDO
PDVVHV,WDOVRVHUYHVDVDEULGJHWROXQJ
transplantation for individual patients and can
be used as a temporizing measure in postoperative patients experiencing respiratory
failure.6,7 By facilitating lung-protective
YHQWLODWLRQ /39 (&02UHGXFHVORQJ
term lung injury by minimizing barotrauma,
volutrauma, atelectrauma, and oxygen toxicity
during recovery.7 Fig. 1 below provides a
depiction of the ECMO circuit.
The inclusion criteria for ECMO vary by
institution. One standard measure is the
Murray Lung score. Scores above 2.5-3
are commonly used to indicate the need
for ECMO.± Uncompensated hypercapnia
with an arterial blood gas pH <7.20 is
another common indication.± A 2018 study
GH¿QHGVHYHUH$5'6LQWKUHHZD\VDV
described in Table 1.9 The Extracorporeal
Life Support Organization (ELSO) has
provided guidelines for ECMO indications
and contraindications as well as special
considerations for management (Table 2).
7KHVHGH¿QLWLRQVDQGSURWRFROVDUHXVHGE\
many institutions worldwide when deciding if
a patient is a candidate for ECMO. Common
contraindications to the use of ECMO include

Introduction
As of March 2021, there have been 124
PLOOLRQ&29,'FDVHVJOREDOO\LQFOXGLQJ
RYHUPLOOLRQGHDWKV,QWKH86
PLOOLRQ&29,'FDVHVKDYHEHHQFRQ¿UPHG
Sept. 2021 | Vol. 3 | Issue 1

Figure 1.'LDJUDPVKRZLQJÀRZRIEORRGIURPSDWLHQWWRPHPEUDQHOXQJDQGEDFNWRSDWLHQWIRU
ECMO support. Blood is drained from the patient at the level of the IVC and returned to the level of the
right atrium. Image courtesy of Dan Johnson, MD. Used with permission.
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end-stage pulmonary disease, multi-system
organ failure, ineligibility for transplantation,
morbid obesity, intracranial bleeding,
contraindications to systemic anti-coagulation,
UHFHQWPDMRU&9$SURORQJHGPHFKDQLFDO
ventilation (usually > 7 days), and age > 65
years.±

PEEP. Driving pressure less than 14 cm
H2O is associated with increased ARDS
survival.10,11,QIDFWD1HZ(QJODQG-RXUQDO
of Medicine (NEJM) article recently showed
a linear relationship between changes in
driving pressure and plasma concentrations of
LQÀDPPDWRU\PDUNHUVOLNH,/,/71)Į,
and others.12

Case

All patients were successfully decannulated
from ECMO during their hospital stay. The
median duration of ECMO treatment was 21
days with the shortest duration being 17 days
and the longest being 27 days. Median length
of hospital stay after decannulation was 24
days. Median length of hospitalization was 47

Three patients at our center have been placed
RQ99(&02IRUVHYHUH$5'6VHFRQGDU\
WRFRQ¿UPHG&29,'LQIHFWLRQ$OO
patients were male with a median age of
\HDUVDQGDPHGLDQ%0,RINJ
m2. Two patients were of Hispanic descent,
while the third was of Asian descent. PreH[LVWLQJPHGLFDOFRQGLWLRQVLQFOXGHGW\SH,,
diabetes mellitus in all patients, one patient
with hypothyroidism, and one patient with
a history of pericarditis in 2018. No patients
had a history of lung disease or tobacco
XVH,QFOXVLRQFULWHULDDWRXULQVWLWXWLRQ
are shown in Table 3 below. These criteria
were developed in response to the increased
PRUWDOLW\RI&29,'LQSDWLHQWVZLWK
certain risk factors including age > 65, male
gender, obesity, hypertension, COPD, diabetes
mellitus, malignancy, and cardiac disease.
,QGLFDWLRQVIRU(&02LQFOXGHGRQHSDWLHQW
with hypoxia (P/F ratio <100), while two
patients were initiated due to combined
hypoxia (P/F <150) and hypercapnia. No
patients received nitric oxide or bicarbonate
infusion prior to ECMO. Prior to ECMO
cannulation, all patients received maximal
medical therapy including neuromuscular
blockade, prone positioning, inhaled
epoprostenol, and maximal lung protective
mechanical ventilation settings. Femoralfemoral venovenous cannulation was
performed for each patient at the bedside.
Ultrasound guidance was used, along with
standard Seldinger technique, for venous
access. Serial dilation was then performed
XQWLOFDQQXODVZHUHSODFHGDQGFRQ¿UPHG
via ultrasonography and chest/abdomen
radiographs. Fig. 2 shows a chest radiograph
of proper ECMO cannula placement.
The median time on mechanical ventilation
before ECMO initiation was six days. The
mechanical ventilation mode utilized was
SUHVVXUHUHJXODWHGYROXPHFRQWURO 359& 
for all patients prior to ECMO initiation.
359&LVWKHSUHIHUUHGYHQWLODWRUPRGHDVLW
allows close monitoring of airway pressures.
Lung protective strategies that emphasize low
tidal volumes and low driving pressure are
fundamental strategies to avoid barotrauma
and volutrauma in these patients. Driving
SUHVVXUHLVGH¿QHGDVSODWHDXSUHVVXUHPLQXV
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GD\VZLWKPHGLDQWLPHLQWKH,&8RIGD\V
Survival at hospital discharge and 60 days
post-hospital discharge were 100%.
Two patients experienced gastro-intestinal
bleeding during treatment on ECMO, with
one patient requiring partial bowel resection.
One patient developed hematuria. All patients
required red blood cell transfusions, with a
median of 17 units during ECMO therapy.
One patient also required transfusion of 3
units of platelets, 2 units of fresh frozen
plasma (FFP), and 10 units of cryoprecipitate.
7KHUHZDVQRLQFLGHQFHRI'97RUVWURNH
All three patients required vasodilators and
vasopressors during their treatment. One

Table 1.
Respiratory and ventilator parameters that qualify for VV ECMO.
1. PaO2:FiO2 <50 mmHg for >3 hours
2. PaO2:FiO2 <80 mmHg for >6 hours
3. Arterial blood pH <7.25 with a PaCO2 >60 mmHg for >6 hours
and RR of 35 bpm
and plateau pressure <32 cm of H2O
and FiO2 >0.8
and Tidal Volume 6 mL/kg
and PEEP >10 cm of H2O
PaO2: arterial oxygen partial pressure; FiO2: fraction of inspired oxygen; PaCO2: arterial carbon dioxide
partial pressure; RR: respiratory rate; PEEP: positive end-expiratory pressure

Table 2.
Indications and Contraindications to placement onto ECMO. P/F: ratio of PaO2 to FiO2.
Indications for ECMO

1. Mortality risk > 80%
2. P/F < 80 with FiO2 > 0.90
3. Murray Lung Score of 3-4

Consideration for ECMO

1. Mortality risk > 50%
2. P/F < 150 with FiO2 > 0.90
3. Murray Lung Score of 2-3

Contraindications to ECMO

1. Conditions incompatible with normal life
2. Pre-existing conditions affecting quality of life
a. CNS status
b. End stage malignancy
c. Risk of systemic bleeding with anticoagulation
3. Age>65
4. Futility
a. Patients who are too sick (ie. Immunosuppression)
b. Have been on conventional therapy too long
(Mechanical ventilation > 7 days)

Table 3.
Inclusion criteria used at UNMC for placement onto VV ECMO for ARDS secondary to SARS-CoV-2
disease.
1. P/F ratio of less than 100 despite aggressive mechanical ventilation including FiO2 of 1.0, PEEP greater
than 16, neuromuscular blockade, +/- prone.
2. Elevated peak airway pressures (greater than 40 mmHg) and/or plateau airway pressures (greater than 30
mmHg) despite lung protective mechanical ventilation and maximal medical therapy.
3. pH of 7.2 or less with inability to correct respiratory acidosis with aggressive mechanical ventilation.
4. PaCO2 of 50 or greater despite maximal medical therapy, aggressive mechanical ventilation, and
respiratory rate greater than or equal to 30 breaths per minute.
5. Mechanical ventilation performed for 3-7 days
6. Can accept patients on mechanical ventilation over 7 days on a case-by-case basis after review and
agreement by all teams.
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patient required inotropic agents, and one
required two minutes of CPR before ROSC
after a tracheostomy change. Two patients
suffered acute kidney injuries, with one
requiring 17 days of continuous venovenous
hemodialysis. Pneumothorax was seen in two
patients. Two patients developed secondary
bacterial pneumonia, while all three patients
had blood cultures displaying gram-positive
organisms. A positive urine culture was
seen in one patient. Fig. 3 depicts these
complications.

Two patients were treated with remdesivir
and one received barcitinib, a JAK-inhibitor.
Prone position was not used while on ECMO.
One patient was discharged home, and two
were discharged to long term acute care.
Sixty-day survival after hospital discharge
was 100% in our patient population. All
patients required tracheostomies during their
hospitalization. Of note, one patient was able
to be decannulated from their tracheostomy
prior to hospital discharge.

Figure 2. Chest x-ray showing diffuse pulmonary opacities consistent with SARS-CoV-2 infection.

'LVFXVVLRQ
All of our patients (100%) in this case series
VXUYLYHGWR,&8GLVFKDUJHKRVSLWDOGLVFKDUJH
and 60 days post-hospital discharge. One
study with a larger patient population with any
ARDS etiology displayed survival to ECMO
,&8GLVFKDUJHRI6 Median duration
of ECMO in the said study was 191 hours,
while ours was 21 days (504 hours).6 Our
patients spent a median time of 47 days in the
hospital, compared to 16 days in the England
study.5,6,QFLGHQFHRISQHXPRWKRUD[LQRXU
patients was 67% compared to an incidence
of 10.4% at other centers.6 Sixty seven of our
patients developed culture-proven bacterial
pneumonia, and 100% developed cultureproven bloodstream infections. Culture
proven infection occurred in only 15% of
patients in the England study.6 A NEJM study
FRPSDUHGVHYHUH$5'6SDWLHQWV GH¿QHG
in the introduction) placed on ECMO to a
control group that only received standard
treatment. Sixty-day survival in the ECMO
group was 65% compared to 54% in the
control group.9 The ECMO group had a
higher incidence of bleeding events requiring
transfusion and severe thrombocytopenia, but
had fewer ischemic stroke cases.9 All patients
in our study required RBC transfusion at some
point during their care. Similarly, no patients
VXIIHUHGIURPVWURNHRU'97GXULQJWKHLU
treatment. All our patients had underlying
SRRUO\FRQWUROOHGW\SH,,GLDEHWHVPHOOLWXV
99(&02SURYLGHVUHOLHIWRWKH
dysfunctional pulmonary system in patients
with severe ARDS, allowing time for lung
recovery. Lung recovery is most effectively
IDFLOLWDWHGWKURXJK/39VWUDWHJLHVWKDW
minimize barotrauma and volutrauma.
,QIDFWPLQLPL]DWLRQRIGULYLQJSUHVVXUH
is associated with increased survival and
UHGXFHGLQÀDPPDWRU\PDUNHUOHYHOVLQ$5'6

Complications on ECMO
Positive Urine Culture
Blood Cultures Positive for Gram-Positive Organisms
Secondary Bacterial Pneumonia
Pneumothorax
AKI*
Necessity for Treatment with Inotropic Agents
Cardiac Arrest Requiring CPR**
Extremes of Blood Pressures Requiring Vasopressor or...
CVA
DVT
Anemia Requiring RBC Transfusion***
Hematuria
GI Bleed****
0

1

2

3

Number of Patients Experiencing Listed Complication

Figure 3. List and number of patients suffering from complications related to or a consequence of ECMO therapy.
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patients.10-12 At the University of Nebraska
Medical Center (UNMC), our standardized
/39SURWRFROLQFOXGHVWLGDOYROXPHVRI
mL/kg of predicted body weight, pressureUHJXODWHGYROXPHFRQWURO 359& YHQWLODWRU
settings, PEEP of 8-16 cm H2O, RR <10 bpm,
plateau pressure < 30 mmHg, and driving
pressure < 15 mmHg if able. These protocols
not only give our patients the greatest chance
of survival, but also help to reduce longterm complications caused by high airway
pressures.

Conclusion
99(&02ZKHQFRPELQHGZLWK/39LVD
powerful, but resource-consuming treatment
modality for patients suffering from severe
ARDS. A robust study in England reported
RISDWLHQWVUHTXLULQJ99(&02IRU
respiratory failure secondary to numerous

FDXVHVVXUYLYHGWR,&8GLVFKDUJH6 Another
substantial study showed 90-day in-hospital
PRUWDOLW\DIWHULQLWLDWLRQRI99(&02LQ
patients suffering severe ARDS secondary to
&29,'LQIHFWLRQZDVVLPLODUWRWKH
PRUWDOLW\UDWHVUHSRUWHGLQQRQ&29,'
cases of severe ARDS.5 Sixty day survival in
our patient cohort was 100%, displaying the
YDOLGLW\RIWUHDWLQJ&29,'LQGXFHGVHYHUH
$5'6ZLWK99(&02DQG/39
An important theme in the study of treating
$5'6ZLWK99(&02LVWKHFDUHIXOVHOHFWLRQ
of patients and use of strict mechanical
ventilation strategies to minimize further
lung damage. ECMO is a resource-intensive
treatment that serves only as a bridge to
recovery or transplant. Therefore, careful
selection of patients with high likelihood
of recovery is necessary. Contraindications
for the practical and effective use of this

treatment modality include, but are not
limited to, end organ failure, minimal hope
of recovery after decannulation, age >65,
advanced cancer diagnosis, morbid obesity,
and recent intracranial pathology. This careful
utilization of resources is essential to the
success of the treatment and patient outcomes.
(&02LVDYLDEOHWUHDWPHQWIRU&29,'
induced severe ARDS. However, especially
in pandemic times and the resulting limitation
in resources, increased selectivity and strict
adherence to protocols are necessary to
HQVXUHWKHEHVWSDWLHQWRXWFRPHV,QRXU
H[SHULHQFH&29,'LQGXFHGVHYHUH$5'6
results in longer duration of ECMO, a longer
GXUDWLRQRI,&8FDUHDQGPRUHH[WHQGHG
hospitalization than other causes of severe
ARDS. 
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